Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IVIG Access Issues Highlighted In Effort To Eliminate Specialty Drug Tiers

Executive Summary

Continued problems with patient access to intravenous immune globulin therapies is helping patient advocacy groups put the spotlight on payers' handling of IVIG on their formularies and make a push for eliminating the use of specialty drug tiers

You may also be interested in...



Industry Pressures CMS To Hold ASP Plus 6 Percent Rate For Hospital Outpatient Drugs

CMS' proposal to bring the reimbursement rate for Medicare Part B drugs administered in hospital outpatient departments back to average sales price plus 6% for the first time since 2007 has resulted in a fresh wave of pressure from industry groups to keep it at that level.

Industry Pressures CMS To Hold ASP Plus 6 Percent Rate For Hospital Outpatient Drugs

CMS' proposal to bring the reimbursement rate for Medicare Part B drugs administered in hospital outpatient departments back to average sales price plus 6% for the first time since 2007 has resulted in a fresh wave of pressure from industry groups to keep it at that level.

FTC Taking A Closer Look At Talecris/Grifols Merger; HIGPA Voices Concerns

The Federal Trade Commission has requested further information from both Talecris Biotherapeutics and Grifols in relation to the two companies' proposed merger

Related Content

Topics

UsernamePublicRestriction

Register

PS052282

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel